Compare Taskus Inc (TASK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs BIO-TECHNE Corp — how do they compare? Taskus Inc trades at $8.14 (market cap $723.41M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 15.7× Taskus Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Taskus Inc for 34 Days and BIO-TECHNE Corp for 64 Days on average.
| TASK | TECH | |
|---|---|---|
Market Cap | $723.41M | $11.36B |
Volume | 201,303 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $14.30 | $72.61 |
52-Week Low | $4.57 | $43.31 |
Typical Hold Time | 34 Days | 64 Days |
Enterprise Value | $1.09B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs trades at $8.01, up 1.52% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with revenue of $308.9M, though Q1 missed expectations. Fundamentals show attractive valuation with P/E of 6.8 and robust profitability metrics including 8.75% net margin and 25.43% ROE. Revenue growth continues at 5% year-over-year, driven by AI services expansion offsetting declines in legacy segments.
The stock presents value opportunity with 16% upside to consensus price target of $9.33, supported by 55% analyst buy ratings. Key risks include margin compression from labor costs and client concentration. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026. Near-term catalyst is Q3 earnings where company must deliver on $0.30 EPS expectations to maintain momentum.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, as the stock approaches its 52-week high of $72.70. The company shows strong profitability with 65.77% gross margins and 14.97% net income margin, though earnings have been mixed with one miss and two beats in recent quarters. Technical indicators show a bullish trend with support at $72 and resistance at $73. Recent news highlights shareholder approval of the Merck KGaA acquisition at $73 per share, providing a clear near-term catalyst.
The acquisition premium offers limited upside from current levels, while fundamental metrics show elevated valuation (P/E 62.46) despite solid profitability. Key risks include integration challenges post-acquisition and potential regulatory scrutiny. Analyst consensus leans neutral with 46% buy ratings and a $65.78 price target below current trading levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
